肿瘤药学2025，Vol.15Issue(3)：322-328,7.DOI:10.3969/j.issn.2095-1264.2025.03.04
多学科讨论合作助力高龄原发难治DLBCL持续缓解——1例疑难淋巴瘤病例MDT诊疗
Multidisciplinary collaboration facilitates sustained remission in elderly patients with primary refractory DLBCL:a case report of MDT management for a complex lymphoma case
曾若兰 1李俊军 1谢爱民 1袁媛 1李亚军 1周辉1
作者信息
- 1. 湖南省肿瘤医院 淋巴瘤血液内科,湖南 长沙,410013
- 折叠
摘要
Abstract
This article reports the multidisciplinary team(MDT)management of an elderly patient with primary refracto-ry diffuse large B-cell lymphoma(DLBCL)complicated by multiple comorbidities,including hypertension,coronary athero-sclerosis,aortic sclerosis,and diabetes.Upon admission,the patient was diagnosed with advanced-stage DLBCL.Based on tolerance assessment,first-line immunochemotherapy(R-CHOP regimen)was initiated but showed suboptimal efficacy.Subsequently,a Bruton's tyrosine kinase inhibitor(BTKi)was added guided by next-generation sequencing(NGS)results,achieving partial response after four cycles.However,disease progression occurred following two additional cycles.After MDT discussion,a bridging therapy combining targeted therapy and radiotherapy was implemented,followed by sequential chimeric antigen receptor T-cell immunotherapy(CAR-T),ultimately leading to complete remission sustained for over one year.This case highlights the challenges in managing elderly patients with primary refractory DLBCL and underscores the value of a multidisciplinary collaborative approach.关键词
弥漫性大B细胞淋巴瘤/多学科诊疗/嵌合抗原受体T细胞免疫疗法Key words
Diffuse large B-cell lymphoma/Multidisciplinary team/Chimeric antigen receptor T-cell immunotherapy分类
医药卫生引用本文复制引用
曾若兰,李俊军,谢爱民,袁媛,李亚军,周辉..多学科讨论合作助力高龄原发难治DLBCL持续缓解——1例疑难淋巴瘤病例MDT诊疗[J].肿瘤药学,2025,15(3):322-328,7.
